Myocarditis data from Korea

19.8% of total VRM was severe COVID-19 vaccination-related myocarditis: a Korean nationwide study Nationwide study, incidence and outcomes of COVID-19 vaccination-related myocarditis (VRM). 44, 276, 704 individuals, at least 1 dose Incidence and clinical courses of VRM cases Diagnosis confirmed by Expert Adjudication Committee of the Korea Disease Control and Prevention Agency COVID-19 VRM 1, 533 presumptive cases Confirmed in 480 cases ( cases per 100 000 persons) Incidence was significantly higher in men Men, per 100 000 persons Women, per 100 000 persons Males aged 12 to 17, cases per 100 000 persons Females over 70, cases per 100 000 persons CDC today COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. Mostly after first or second dose mRNA vaccines compared to other vaccines VRM after mRNA vaccines, per 100 000 persons VRM after AZ vaccine, per 100 000 persons P les than Denmark, VRM BNT162b2, 1.4 per 100 000 vaccinated individuals mRNA-1273, 4.2 per 100 000 (within 28 days of vaccination) Severe VRM was identified in 95 cases 19.8% of total VRM ( per 100 000 vaccinated persons) 85 intensive care unit admission (17.7% of total VRM) 36 cases of fulminant myocarditis 7.5% of total VRM 21 cases required extracorporeal membrane oxygenation (4.4% of total VRM) 21 more severe adverse events (4.4% of total VRM) Eight out of 21 were sudden cardiac dea*** (SCD) (attributable to VRM proved by an autopsy) All cases of SCD attributable to VRM were aged under 45 years and received mRNA vaccines 1 heart transplantation Conclusion Moreover, SCD should be closely monitored as a potentially fat** complication of COVID-19 vaccination. Most common presenting symptom Chest pain or discomfort Median time from the vaccination to symptom onset, 3 days (IQR, 1–10 days) COVID-19 VRM incidence was highest in mRNA-1273 vaccine (Moderna) Followed by BNT162b2 J and J Ad26 per 100 000 persons AZ ChAdOx1 per 100 000 persons